GSK Viiv Extends Cabotegravir Licensing Deal to Include HIV Treatment

MT Newswires Live
07/14

GSK's (GSK) majority-owned ViiV Healthcare said Monday it extended its voluntary licensing agreement with the Medicines Patent Pool to cover the use of cabotegravir in a long-acting HIV treatment regimen.

The updated agreement allows existing licensees, including Aurobindo, Cipla and Viatris (VTRS), to develop, manufacture, and supply generic long-acting injectable cabotegravir for use with rilpivirine to treat HIV-1 in patients aged 12 and older weighing at least 35 kilograms, subject to regulatory approvals.

The expanded license follows updated World Health Organization guidance recommending long-acting injectable cabotegravir and rilpivirine as a treatment option.

It builds on an existing agreement covering the use of cabotegravir in HIV pre-exposure prophylaxis and is intended to broaden access in 133 countries, including all least-developed, low-income and lower middle-income countries, as well as Sub-Saharan Africa and markets where ViiV holds no cabotegravir patents.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10